Myostatin and sarcopenia: Opportunities and challenges - A mini-review

Thomas A. White, Nathan K. Lebrasseur

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations


The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
Issue number4
StatePublished - Jun 2014


  • Aging
  • Atrophy
  • Diabetes
  • Drug discovery
  • Frailty
  • Growth and differentiation factor
  • Obesity
  • Skeletal muscle

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology


Dive into the research topics of 'Myostatin and sarcopenia: Opportunities and challenges - A mini-review'. Together they form a unique fingerprint.

Cite this